Apimeds Pharmaceuticals US, Inc (APUS) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in Hopewell, NJ, United States. The current CEO is Youngjik Cho.
APUS has IPO date of 2025-05-09, 2 full-time employees, listed on the American Stock Excha, a market capitalization of $2.36M.
Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey. Apimeds Pharmaceuticals US, Inc. is a subsidiary of Api Meds, Inc.
